Under the contract, DNAe will develop tests for antimicrobial resistant infections and influenza that it submits to the FDA for clearance.
Premaitha said it has sold more than 17,000 of the tests, which is the focus of an ongoing patent-infringement suit, since its launch in early 2015.
The bill comes amid questions about the efficacy of Epigenomics' Epi proColon, the only blood-based cancer screening test approved in the US.
Rosetta's test is designed to analyze the expression of microRNA biomarkers in indeterminate thyroid fine needle aspirate smears to differentiate benign thyroid nodules from malignant ones.
CareFirst covers more than 3 million patients in Maryland, Washington DC, and Virginia, and is one several payors to recently issue a coverage decision for Vermillion.
In Nature this week: genetic link between birth weight and adult-onset diseases, and more.
Even with all the current enthusiasm for gene therapies, Tech Review cautions that they are mostly in the early stages of development.
DNA phenotyping puts a potential face to a suspect in a nearly 25-year-old murder, the AP reports.
Researchers discuss the need for antibody standards at a meeting, NPR reports.